knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 14:59:57 - browse：51

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

knowledge

WSS

Obesity drugs seen as possible treatment for liver disease MASH

Medicare inequities exacerbate Puerto Rico’s health disparities

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Antivenom research: Lessons from HIV applied in search for universal antidote

Alabama frozen embryo ruling has major implications for IVF clinics

Surgery pushed Ben Carson to fame

knowledge

knowledge

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

As demand for Covid shots wanes, Moderna seeks its next success

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Novavax promises a turnaround & Lilly roils the obesity market

Alabama IVF ruling threatens families facing fatal genetic disease

Anesthesiologist group: stop taking Ozempic before surgery

What’s missing from the debate over nursing home staff minimums

23andMe had bad news about my health. I wish a person had delivered it

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

explore

NIH study of ME/CFS points to clear biological hallmarks

The Biogen Aduhelm mess could happen again

The Biogen Aduhelm mess could happen again

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Antivenom research: Lessons from HIV applied in search for universal antidote

entertainment

Wikipedia

knowledge

focus